SHZ · 000990.SZ
Chengzhi Shareholding Co., Ltd.
CN¥4.93-CN¥0.12 (-2.38%)
Chengzhi Shareholding Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.59% below the high.
Loading market information…
SHH · 688136.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Kexing Biopharm Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kexing Biopharm Co., Ltd.’s forward annual dividend is CN¥0.25 per share, paid annual. The forward yield is 1.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Kexing Biopharm Co., Ltd.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kexing Biopharm Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥4.93-CN¥0.12 (-2.38%)
Chengzhi Shareholding Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.59% below the high.
CN¥14.98+CN¥1.36 (+9.99%)
Guilin Sanjin Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
CN¥7.27+CN¥0.06 (+0.83%)
Zhejiang Ausun Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.75% below the high.
CN¥37.84+CN¥0.31 (+0.83%)
Hangzhou Biotest Biotech Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.77% below the high.
CN¥11.14-CN¥0.07 (-0.62%)
Wuhan Keqian Biology Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.45% below the high.
CN¥4.98-CN¥0.03 (-0.6%)
Beijing SL Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.02% below the high.
CN¥10.10-CN¥0.04 (-0.39%)
Hunan Jiudian Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.85% below the high.
CN¥21.29-CN¥0.67 (-3.05%)
Zhejiang AngLiKang Pharmaceutical CO.,LTD.’s quoted price sits in the lower half of its reported 52-week range, 56.46% below the high.
